Table 2.
(a) Association of estrogen and progesterone receptor immunoexpressions between primary and recurrent tumors (the Immunoreactive Score system). (b). Association of estrogen and progesterone receptor immunoexpressions between primary and recurrent tumors (Allred Total Score System).
| (a) | ||||
|---|---|---|---|---|
| Primary Tumors | Recurrent Tumors | p-Value | ||
| Estrogen Receptor | sensitive | 12/52 (23.1 %) |
9/50 18.0 % |
0.74 |
| resistant | 7/21 (33.3 %) |
4/21 19.0 % |
0.99 | |
| p-value | 0.57 | 0.28 | ||
| Progesterone Receptor | sensitive | 14/48 (29.2 %) |
7/52 (13.5 %) |
0.030 |
| resistant | 5/21 23.8% |
3/20 15.0 % |
0.56 | |
| p-value | 0.84 | 0.69 | ||
| (b) | ||||
| Estrogen Receptor | sensitive | 17/52 (32.7%) |
17/50 (34.0 %) |
0.84 |
| resistant | 9/21 (42.9%) |
11/21 (52.4 %) |
0.75 | |
| p-value | 0.65 | 0.31 | ||
| Progesterone Receptor | sensitive | 15/48 (31.3 %) |
10/52 (19.2 %) |
0.023 |
| resistant | 6/21 (28.6 %) |
5/20 (25.0 %) |
0.52 | |
| p-value | 0.73 | 0.67 | ||
Table 2a shows the association of estrogen and progesterone receptor immunoexpressions (Immunoreactive scoring systems) of primary and recurrent tumors and in chemotherapy (platinum-based)-sensitive and -resistant cases. p-values of independent data are based on unpaired Wilcoxon tests on original scores. p-values of dependent data are based on paired Wilcoxon tests on original scores. Table 2b shows the association of estrogen receptor and progesterone receptor immunoexpressions (Allred Total Score) of primary and recurrent tumors and in chemotherapy (platinum-based)-sensitive and –resistant cases. p-values of independent data are based on unpaired Wilcoxon tests on original scores. p-values of dependent data are based on paired Wilcoxon tests on original scores.